ArkAb new products anti-SARS-COV-2

ArkAb new products anti-SARS-COV-2

ArkAb developed products in response to COVID-19 pandemic. 

ArkAb and B Cell Design are developing a program to provide raw materials for the quality controls of immunoassays looking for Ig anti-SARS-COV-2 in human samples. This project was founded by the French Ministry of the Armed Forces. ArkAb developed human chimeric monoclonal antibodies (huchimAbs) as an alternative to disease state plasma for immunoassay quality controls. These products will be available for IVD manufacturers first quarter of 2021. 

Contact your ArkAb representatives or follow THIS LINK to book your products!


ArkAb worked on several SARS-COV2 proteins: spike, spike subunit S1, nucleocapsid, Receptor Binding Domain (RBD).

ArkAb team prepared several cohorts of its patented technologies:

  • GammaPrim®
  • InEps®


Then let’s take as example HAMIGA® immunization with spike protein.

During immunization, ArkAb monitored immune answers by in-home ELISA and covidot test from d-tek, (and an adapted version for IgM and IgA).

The in-home ELISA was designed with patient samples confirmed positive and negative for SARS-COV-2 infections.

Below is a sample of HAMIGA® immune answer against SARS-COV-2 Spike protein.

HAMIGA immune answer anti-SARS-COV-2 Spike

Once immune answer was sufficient, ArkAb immortalized B cells splenocytes by cell fusion with sp2-0 cells.

Hybridomas were screened by ArkAb with in-home ELISA, then Covidot from d-tek, adapted in IgA.

To insure stabilization of cell lines producing specific huchimAb, limit dilutions were made on most reactive hybridomas and samples became available for several partners showing their interest to test research products.

ArkAb wants to thank very much all partners who tested a large selection of clones in their own applications, they will recognize themselves!

The results of these tests are important for ArkAb to select the right clones to be saved and stabilized, and that will become an industrial product. First industrial batches are expected during first quarter of 2021. Please visit the PRODUCTS LIST to find the ones corresponding to your needs and/or contact your ArkAb representatives or HERE for more information.

Further characterization of pre-selected huchimAbs are done with antibodies neutralizing activity tests. As expected only antibodies reactive against RBD show a neutralizing activity. Further tests are made nowadays. These human chimeric antibodies will be used as tools to develop rapid tests to assay neutralizing antibodies in patient mucosal samples.

They might be used in a second time by B Cell Design to develop a drug candidate as a nasopharyngal spray against COVID-19.

ArkAb and B Cell Design are eagerly looking forward to next opportunity to welcome you within the companies or on trade fair booth, to introduce you in more details the range of human chimeric antibodies against COVID-19.

Go back

This website uses cookies, by continuing to browse this website you agree to our cookie policy.